Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614354 · ClinicalTrials.gov registry record · Phase 2
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
A Phase 2 study, sponsored by Molecular Targeting Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00614354 is a Phase 2 study that has completed, run by Molecular Targeting Technologies. The registered enrollment target is 66 participants.
The verdict
NCT00614354, a Phase 2 study, has completed, sponsored by Molecular Targeting Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.
Interventions
- DRUG 99mTc-glucarate solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00614354
The ClinicalTrials.gov registry entry for NCT00614354 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Targeting Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 99mTc-glucarate solution is the first listed.
NCT00614354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00614354 about?
NCT00614354 is a clinical study titled "Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.". The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The...
What is the current status of trial NCT00614354?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2008-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00614354?
The interventions under investigation include: 99mTc-glucarate solution (DRUG).
Who is sponsoring clinical trial NCT00614354?
This trial is sponsored by Molecular Targeting Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.